Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

GDUFA Negotiations Shift To 'Tiered' Fee Models

Executive Summary

Finance subgroup talks about new structure for generic drug user fee program that could mean bigger firms would pay more.


Related Content

GDUFA II: ANDAs, Not Facilities Will Govern Revenue
ANDA User Fees Offer Sponsor Relief, But More Facility Pain
Sponsors, FDA Reviewers To Get More Flexibility Under New User Fee Program
Two Out Of Three Ain't Bad: Biosimilar User Fee Talks Completed
GDUFA II: FDA, Industry Reach Tentative 'Alignment' On ANDA Review Issues
Dark, Then Dawn: ANDA Workload Approaching Steady State After 2014 Eruption
Generic User Fee 'Relief' For Small Firms Would Mean Bigger Bills For Large One
GDUFA II: Facility Fees Might Be Deferred Until ANDA Approval
ANDA Avalanche: How Will FDA Deal With The 600 Received This Month?
Generic User Fee Waivers Created In Draft House Bill, Breaking FDA-Industry Agreement